Thursday, August 14, 2025 12:56:22 AM
Sure, approval will cause a share price spike. I'm not arguing that. The shorts will let it run up and then start shorting it back down as soon as the initial run looses steam. They won't be able to short back down to the price prior to the run of course.
I doubt that single digit short interest is going to make for a short squeeze.
Your faith in the "locked in long term retail holders" is much stronger than mine.
There are a lot of people that have posted that they will be more than happy to sell as soon as the SP hits breakeven for them. There are also a lot of people that will bail when they hit 100 to 200% gains. There are a whole lot of frustrated shareholders that want to done with NWBO.
Form the current share price a 10 bagger is a share price of $2.50.
What might sustain a share price run up is if the company has a series of PRs, that are properly spaced, of funding, partnerships, additional trials. But that is no different than ordinary business for a developmental biotech that has a good treatment that has just been approved.
MM can legally short to make a market. They do that all the time when there is a sudden info shock to the share price and volume. There is no reason to think that NWBO will be any different.
I'd love to see the SP hit $10 on the approval news. Not holding my breath on that.
I doubt that single digit short interest is going to make for a short squeeze.
Your faith in the "locked in long term retail holders" is much stronger than mine.
There are a lot of people that have posted that they will be more than happy to sell as soon as the SP hits breakeven for them. There are also a lot of people that will bail when they hit 100 to 200% gains. There are a whole lot of frustrated shareholders that want to done with NWBO.
Form the current share price a 10 bagger is a share price of $2.50.
What might sustain a share price run up is if the company has a series of PRs, that are properly spaced, of funding, partnerships, additional trials. But that is no different than ordinary business for a developmental biotech that has a good treatment that has just been approved.
MM can legally short to make a market. They do that all the time when there is a sudden info shock to the share price and volume. There is no reason to think that NWBO will be any different.
I'd love to see the SP hit $10 on the approval news. Not holding my breath on that.
Nunc est Bibendum
Recent NWBO News
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/26/2025 05:15:34 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
